- Japan
- /
- Life Sciences
- /
- TSE:7079
WDB coco Third Quarter 2025 Earnings: EPS: JP¥82.75 (vs JP¥85.24 in 3Q 2024)
WDB coco (TSE:7079) Third Quarter 2025 Results
Key Financial Results
- Revenue: JP¥1.39b (up 15% from 3Q 2024).
- Net income: JP¥199.0m (down 2.9% from 3Q 2024).
- Profit margin: 14% (down from 17% in 3Q 2024). The decrease in margin was driven by higher expenses.
- EPS: JP¥82.75 (down from JP¥85.24 in 3Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
WDB coco's share price is broadly unchanged from a week ago.
Risk Analysis
Be aware that WDB coco is showing 1 warning sign in our investment analysis that you should know about...
Valuation is complex, but we're here to simplify it.
Discover if WDB coco might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:7079
WDB coco
Provides contract services to pharmaceutical companies in Japan.
Flawless balance sheet with solid track record.
Market Insights
Community Narratives
![ChadWisperer](https://lh3.googleusercontent.com/-XdUIqdMkCWA/AAAAAAAAAAI/AAAAAAAAAAA/4252rscbv5M/photo.jpg)